Kornimate/medical-research-clean huggingface dataset:
effect of liraglutide combined with short-term csii on long-term glycemic remission and β cell function

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to investigate and evaluate the effects of liraglutide combined with short-term continuous subcutaneous insulin infusion(csii) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.

the purpose of this study is to investigate and evaluate the effects of liraglutide combined with short-term continuous subcutaneous insulin infusion(csii)(1.csii alone; 2.liraglutide combined with csii) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.

Eligibility criteria:
inclusion criteria: * newly diagnosed type 2 diabetes * fasting blood glucose (fbg) level ranging from 7.0-16.7mmol/l * body mass index (bmi) ranging from 21-35kg/m2 * antihypercaemic and antihyperlipidemic medication-naive patients exclusion criteria: * having any severe acute or chronic diabetic complications * renal dysfunction, blood creatinine\>150umol/l * blood aminotransferase level rising up(more than 2 times of the upper normal limit of alt) * any severe cardiac disease including congestive cardiac failure, unstable angina or myocardial infarct in 12 months * chronic or acute pancreatic disease * severe systemic diseases or malignant tumor * female patients incline to be pregnant * being treated with corticosteriod, immunosuppressing drugs or cytotoxic drugs * poor compliance
safely change from bosentan to ambrisentan in pulmonary hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: the primary objective of this study is to assess the safety and tolerance of changing patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.

the therapy of pulmonary arterial hypertension (pah) has been revolutionized with the development and subsequent instruction of oral endothelin receptor antagonists (era). the first approved era, bosentan (tracleer, actelion, inc.) is an effective drug widely used throughout the world in the therapy of pah. newer era's, with purported advantages over the first approved drug have since been tested and subsequently been approved for the therapy of pah in the usa and other countries including ambrisentan (letairis, gilead sciences, inc.). however, there is little data available on the efficacy, safety and tolerability of the elective change from oral bosentan to oral ambrisentan in pah.

Eligibility criteria:
inclusion criteria: 1. patients followed routinely in the pulmonary vascular disease clinic at the university of alabama in birmingham, greater than or equal to 19 years of age. 2. world health organization (who) pah type i 3. who class i-iv symptoms (no functional class exclusion). 4. on bosentan, twice a day, with a maximum daily dose of 250mg, on a stable dose for 3 months with no clinical indication to discontinue the drug (i.e., increased liver function studies or other intolerance). patients may be on other drug therapies for pah, and also may be on oxygen therapy (intermittent or continuous). exclusion criteria: 1. known intolerance or allergy to ambrisentan. 2. prior therapy with ambrisentan. 3. current therapy with two phosphodiesterase-5 inhibitors. 4. change in other approved therapy for pah (including phosphodiesterase-5 inhibitors and prostanoids) within 4 weeks of baseline study visit. 5. planned addition of prostanoid for clinical reasons within 3 months of baseline study visit. 6. active participation in another clinical study involving the medical therapy of pah. 7. uncontrolled systemic hypertension or angina pectoris 8. serum creatinine greater than 2.5 at or within 4 weeks of baseline. 9. serum liver function studies greater than 3 x normal at or within 4 weeks of baseline study visit. 10. in the opinion of the investigator, a change in pah therapy would present significant risk to the subject. 11. in the opinion of the investigator, the participant is unlikely to survive for 12 weeks after study entry. 12. in the opinion of the investigator, the participant is likely to undergo lung or heart-lung transplantation within 12 weeks of study entry. 13. a woman of childbearing potential who is not using an acceptable form of contraception. 14. pregnancy. 15. in the opinion of the investigator, a participant who is not capable or willing to follow the study procedures.

Keywords: pulmonary arterial hypertension pah who group 1
do nanobubbles improve joint hypoxia?

Conditions: Rheumatoid Arthritis; Psoriatic Arthritis

Summary: inflamed joints in patients with rheumatoid arthritis and psoriatic arthritis are characterized by low oxygen levels and inflammation. we propose to investigate whether tiny bubbles (nanobubbles) when given in a drink can alter oxygen level in joints. these nanobubbles are so small that they can enter the bloodstream when given as a drink. this information will give new information on the role of oxygen in joint inflammation and could possibly lead to new treatment approaches in the future.


Eligibility criteria:
inclusion criteria: * • participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 years or above. * fulfil american college of rheumatology/european league against rheumatism criteria (acr/eular) 2010 rheumatoid arthritis classification criteria or fulfil classification criteria for psoriatic arthritis 2006 (caspar). * selected joint for biopsy must be minimum grade 2 synovial thickening for large joint (knee) and medium joint (wrist), or minimum grade 3 synovial thickening for small joint (metacarpophalangeal). * women of child bearing potential who are willing to use effective contraception (i.e. barrier, oral contraceptive pill, implanted contraception, or previous hysterectomy, bilateral oophorectomy) for the duration of the study. exclusion criteria: * • currently on oxygen therapy. * current enrolment in any other clinical study involving an investigational study treatment. * pregnant or lactating, or women planning to become pregnant or initiating breastfeeding. * intramuscular, intravenous or intra-articular administration of corticosteroid within 4 weeks prior to baseline visit. * oral corticosteroid \> 10 mg/day prednisolone or equivalent within 4 weeks prior to baseline visit. * oral corticosteroid dose not stable for at least 4 weeks prior to baseline visit. * oral non-steroidal anti-inflammatory drugs (including aspirin \> 75 mg/ day and selective-cyclooxygenase inhibitors) dose not stable for at least 4 weeks prior to baseline visit. * disease modifying anti-rheumatic drugs (dmards) dose not stable for at least 4 weeks prior to baseline visit. * history of septic arthritis. * participants on warfarin, heparin, low molecular weight heparin, direct oral anticoagulants. oral anti-platelet agents are permitted. * history of haemophilia.
evaluation of the efficacy and tolerability of an exclusion diet in patients with juvenile idiopathic arthritis

Conditions: Juvenile Idiopathic Arthritis (JIA)

Summary: the jia-ed study is a pilot project. based on experience in another inflammatory disease, a 4-week period was extrapolated as sufficient to assess the effectiveness of the experimental intervention. this observation is supported by literature data showing that, halfway through phase i of the cded (crohn diseasse exclusion diet), it is already possible to identify a subset of patients with crohn's disease who are responsive to the dietary treatment and who also have a higher likelihood of achieving clinical remission by the end of the first phase of the diet itself.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of juvenile idiopathic arthritis (jia) in the forms of enthesitis-related arthritis and oligoarticular forms according to the ilar 2001 criteria (https://medicalcriteria.com/web/reujia/); * age between 6 and 18 years (not yet 18); * active disease of mild to moderate severity, assessed through the juvenile - arthritis disease activity score (jadas10) tool (trincianti c. et al., american college rheumatology, 2021); * for study groups 2 and 3: failure of ongoing pharmacological therapy at the time of screening, defined as a failure to achieve at least a 20% reduction in jadas10 values after 3 months of initiating dmard therapy or biologic medication, or if the disease is inactive on such therapy, a 20% increase in those values; * signed informed consent. exclusion criteria: * patients requiring systemic immunosuppressive therapy for active uveitis; * patients undergoing therapy with systemic corticosteroids (defined as prednisone equivalent \>0.5 mg/kg for \>7 days) or intra-articular corticosteroids in the 3 months prior to enrollment; * patients with fecal calprotectin values \> 250 mcg/g at the time of screening; * use of antibiotics in the month prior to enrollment.

Keywords: jia cded dietary therapy
diabetes and metabolic postprandial responses

Conditions: Type 2 Diabetes; Overweight

Summary: the aim of this trial was to compare postprandial metabolic response to glucose load in healthy overweight and type 2 diabetic subjects, by using glycemia, insulinemia, lipid profile, nutrient oxidation follow-up. stable isotopes of glucose were used to assess postprandial total,exogenous and endogenous glucose kinetics.


Eligibility criteria:
inclusion criteria: * overweight or obese volunteers * healthy for one group nd type 2 diabetic for the second group * age between 30 and 65 years old * total cholesterol \< or = 7 mmol/l and triglycerides \< or = 4 mmol/l * for diabetic group: treated by metformin and/or sulfonylurea and/or thiazolidinedione and hba1c \< 6% * stable weight over last 3 months * informed consent exclusion criteria: * no compliant subjects * participation in an other trial 2 months before starting this one * ward of court or under guardianship (sheltered adults) * person deprived of freedom by judicial or administrative decision * type 1 diabetes and type 2 diabetes treated bu insulin or acarbose * existence of a previously diagnosed pathology (other than type 2 diabetes) * previous gastro-intestinal pathology * treated by corticoids, anorexigens, weight loss medicines * alcoholism or severe tobacco consumption

Keywords: type 2 diabetic subjects
the brugada syndrome: a follow-up study

Conditions: Brugada Syndrome

Summary: although for many years the brugada syndrome has been labelled as a purely electrical disease in the structurally normal heart, the evolution of imaging techniques has enabled the discovery of subtle morphofunctional alterations in some of the brugada syndrome patients. we will use new echocardiographic techniques to assess cardiac function in these patients and new parameters will be evaluated for their prognostic value as risk stratificators.


Eligibility criteria:
inclusion criteria: * 18 years or older * diagnosis of brugada syndrome exclusion criteria: * history of pericarditis, ischemic heart disease, cardiomyopathy of any origin, structural heart disease, or any other channelopathy
exercise training in patients with coronary heart disease and type 2 diabetes

Conditions: Coronary Artery Disease; Diabetes Mellitus, Type 2; Atherosclerosis

Summary: diabetes mellitus (dm) is an important risk factor in the development of cardiovascular disease, and people with type 2 diabetes have a two- to four-fold increased risk for cardiovascular morbidity and mortality. physical activity is a well established therapeutic modality for type 2 diabetes. in patients with coronary artery disease (cad), several clinical trials have shown reduced mortality and reduced progression of atherosclerosis with lifestyle intervention including physical activity. but few studies have investigated the effect of physical training in patients suffering from both diseases. the aim of this study is to investigate the effect of one year of organized physical exercise in patients with both coronary heart disease and type 2 diabetes on glucometabolic state and progression of atherosclerosis. the project is a randomized, controlled, open study on physical exercise. 136 patients will be randomized at inclusion to a physical exercise group or a control group, the latter with "normal" follow-up and not discouraged form physical activity. the intervention period will be 12 months, and the physical training program will be developed and conducted in collaboration with norwegian school of sport sciences. the inclusion of patients started summer 2010, the exercise program begins in september 2010 and the practical issues of the study is planned to end during spring 2012. the main hypothesis is that physical exercise improves the glucometabolic state and reduces progression of atherosclerosis in patients with coronary heart disease and type 2 diabetes, and secondary that physical exercise induces favourable changes in cardiovascular risk factors, use of medication, and co-morbidity associated with diabetes.


Eligibility criteria:
inclusion criteria: * coronary artery disease * type 2 diabetes exclusion criteria: * serious diabetic retinopathy, nephropathy and/ or neuropathy * other serious diseases like cancer, stroke or mi last three months, unstable angina, decompensated heart failure, serious ventricular arrhythmia, aortic aneurism, serious valvular heart disease, chronic obstructive pulmonary disease gold classification iv, deep venous/ pulmonary embolism, ongoing infections, serious musculoskeletal disorders. * other serious limitations to physical exercise * pathological exercise stress test warranting further cardiovascular examination

Keywords: coronary artery disease atherosclerosis. diabetes mellitus, type 2 exercise hba1c carotid atherosclerotic disease inflammation
conservation of red cell mass , oxygen supply and demand in cardiac surgery

Conditions: Coronary Artery Disease

Summary: fifty patients will be enrolled into the study. the purpose of the study is to investigate the relevance of hct levels in determining need for transfusion during operations employing bypass as well as to test the hypothesis that, while hct levels may decrease during surgery , red blood cell mass and tissue oxygenation remain fairly constant.

fifty adults( male or female-nonpregnant) whose weight is between 55-85 kg and are scheduled to undergo elective cardiac surgery with cardiopulmonary bypass for cabg or primary valve repair or replacement will be eligible. patients with any history of abnormal bleeding disorders, urgent or emergent need for surgery, and combination surgeries will be excluded. blood volume analysis will be performed with the daxor blood volume analyzer bva-100 system and the volumex hsa i-131 radiopharmaceutical for use for determining circulating volume. multiple timed sample points will be obtained. the daxor blood volume analyzer will batch samples and with input of patients height, weight, gender, time of draw, and corresponding hct, calculate circulating total blood volume. we hypothesize that total red cell mass is relatively well conserved( \<20% decrease) during and immediately after surgery as long as major bleeding does not occur. we hypothesize that decrease in hct during surgery are related to changes in circulating plasma volume. total red cell o2 carrying capacity and o2 economics will be measured and it is also hypothesized that lowered hct values, even as low as 15%, do not independently signal a tissue or whole body o2 deficit.

Eligibility criteria:
inclusion criteria: * patient scheduled to undergo elective cabg or primary repair/replacement on bypass pump. * age 18 yrs or older * male or non pregnant female * weight between 55-85 kg. exclusion criteria: * any known bleeding risks; * urgent or emergent surgery; * combined aortic and major vascular surgery; * pregnant women * if participating in another study within last 90 days.

Keywords: transfusion regulation
safety and efficacy of fluoxetine in pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: this study will evaluate the safety, tolerability and efficacy of open-label fluoxetine for three months among patients with pulmonary arterial hypertension.

idiopathic pulmonary arterial hypertension (pah) is a life-threatening disorder of uncertain cause that leads to progressive right heart failure and death. average survival has improved from about 2.8 years in the early 1990s to approximately 5-7 years with current treatments, but most patients will still die of their disease. two classes of oral medications are approved for use in pah: endothelin-1 antagonists, and phosphodiesterase-5 inhibitors. both improve walk distance and symptoms in pah, but most patients still have continued dyspnea, fatigue and significant elevations in pulmonary pressures. those who remain severely impaired are generally started on a continuous intravenous prostacyclin. for those who are less ill but still symptomatic, few options are available. primary endpoint: the primary endpoint will be change in pulmonary vascular resistance (pvr) measured by right heart catheterization after three months of therapy. secondary endpoints * six minute walk distance * qids-sr depression scale safety and tolerability endpoints will include a tabulation of adverse events to include but not limited to: * death * hospitalization * symptomatic hypotension * gastrointestinal side effects * depression

Eligibility criteria:
inclusion criteria: 1. signed informed consent prior to any study-mandated procedure 2. pah of the following subtypes: idiopathic pah who functional class ii-iii 3. catheterization within one week showing mpap \>=25, wedge or lv end diastolic pressure ≤15, and pvr \> 4 wood units, and baseline fick cardiac output results available 4. age 16-75 5. able to complete a six minute walk distance 6. women of childbearing potential\*: negative serum pre-treatment pregnancy test + consistently and correctly uses a reliable method of contraception\*\* oral approved pah therapy for \>3 months with no change in dose for \> 1 month exclusion criteria: 1. pah with connective tissue disease, congenital heart disease, portal hypertension, glycogen storage disease, gaucher's disease, hereditary hemorrhagic telangiectasia, hemoglobinopathy, myeloproliferative disorders. 2. moderate to severe obstructive or restrictive lung disease: forced expiratory volume in 1 second/forced vital capacity (fev1/fvc) \< 70% and fev1 \< 60% of predicted value after bronchodilator administration. -or- total lung capacity (tlc) \< 60% of predicted. 3. systemic systolic blood pressure \<100 mmhg breastfeeding 4. significant liver, renal or other medical disease preventing completion of the study procedures or with life expectancy \<12 months, or any other acute or chronic physical impairment (other than dyspnea), limiting the ability to comply with study requirements

Keywords: pulmonary arterial hypertension pulmonary hypertension
gingival recession treatment using two different surgical techniques

Conditions: Gingival Recession; Root Planing

Summary: coronally the advanced flap is considered a predictable treatment of gingival recession but in certain situations, it needs a filler like subperiosteal connective tissue graft (ctg) which is considered as the gold standard treatment approach. this randomized controlled trial compares the clinical benefits and effectiveness of a xenogenic collagen matrix (mucoderm, botiss, dental, berlin, germany) as a filler to the subperiosteal connective tissue graft (ctg).


Eligibility criteria:
inclusion criteria: * -the selected patients for this study are non-smokers, aged 18-60 years with multiple gingival recession (miller class 1, or 2.) for more than two adjacent affected teeth with plaque score less than 25% exclusion criteria: * -patients with systemic complications, psychological problems, parafunctional habits, or patients presented with mal-posed teeth, hypermobile teeth, teeth with miller class 3 gingival recession were excluded from this study.

Keywords: root coverage mucoderm connective tissue grafts
training physicians to differentiate the paris classification using artificial colon polyp images

Conditions: Colonic Polyp; Colon Adenoma

Summary: training in endoscopy is essential for the early detection of precursors of colorectal cancer. up to now, this training has been carried out with image collections of findings and in practice when working on patients. we want to use artificial intelligence (ai) to better train doctors to recognise these precursors. by using generative ai, we were able to create realistic images that comply with data protection regulations and whose content can be predefined. parts of the image can also be regenerated so that it is possible to create different precancerous stages in the same place in the image. in this study we want to train physicians using real images or artificial images in order to compare which version helps classify polyps better.


Eligibility criteria:
inclusion criteria: * physicians with or without experience in colonoscopy

Keywords: colonoscopy
treatment of cd20 antibody plus cik for patients with refractory lymphomas

Conditions: Lymphomas

Summary: to study the safety and efficacy of cd20 antibody usage followed by cik transfusion in refractory and/or chemoresistant lymphomas.

autologous cik transfusion within 3 days post cd20 antibody treatment.

Eligibility criteria:
inclusion criteria: - diagnosed as b-cell lymphoma with cd20 positiveness, and need to therapy exclusion criteria: - to refuse the therapy and need not tolerate the therapy

Keywords: mabthera cytokine induced killer cell